Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + toripalimab
- Development stage
- Phase 3
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Anlotinib + toripalimab is a combination therapy consisting of two distinct agents used primarily in oncology. Anlotinib is a small molecule multi-targeted tyrosine kinase inhibitor that inhibits angiogenesis and tumor cell proliferation by targeting receptors such as VEGFR, FGFR, PDGFR, and c-Kit. Toripalimab is a recombinant humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells, functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. This combination has shown promising efficacy and manageable safety in several cancer types including unresectable hepatocellular carcinoma (HCC), advanced gastric or gastroesophageal junction carcinoma, metastatic melanoma, advanced esophageal squamous cell carcinoma (ESCC), undifferentiated pleomorphic sarcoma (UPS), and extensive-stage small-cell lung cancer (ES-SCLC). The regimen leverages the synergistic effects of antiangiogenic therapy with immunotherapy to improve clinical outcomes[1][3][4][5][6][7].
- Brand names
- TuoyiFukanghua
- Other names
- anlotinib plus toripalimabtoripalimab plus anlotinib
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on anlotinib + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + toripalimab.